The University of Chicago Header Logo

Connection

Michael Quinn to Carboplatin

Back to Details
This is a "connection" page, showing publications Michael Quinn has written about Carboplatin.
Michael Quinn
Connection Strength
0.015
Carboplatin
  1. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2005 Mar 01; 11(5):1890-8.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.